A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide

Ki vehet részt

• Age > 18 years, regardless of gender
• Newly diagnosed patients with follicular lymphoma (Grade 1, 2, or 3a) confirmed histologicallyaccording to the World Health Organization (WHO) classification of diseases
• Deemed by the investigator to have an indication for treatment and require therapy
• ECOG performance status score of 0-2
• Laboratory tests meeting the following criteria:; Bone marrow hematopoietic function is essentially normal: WBC 3.5x10\^9/L, ANC > 1.0x10\^9/L, PLT > 75x10\^9/L, Hb > 80 g/L; Liver function: AST/ALT s 2xULN, TBILI s 2xULN; Renal function: Creatinine clearance rate > 50 ml/min;6. Presence of at least one measurable lesion: Lymph node lesion with a long diameter > 1.5 cm orextranodal lesion with a long diameter > 1.0 cm as shown by PET/CT, CT, or MRl, or a lesion > 2cm assessed by clinical examination
• Ability to provide written informed consent

Ki nem vehet részt

• Patients with active hepatitis B (HBV, hepatitis C (HCV, or other acquired/congenitalimmunodeficiency diseases
• Patients with severe active infections requiring systemic antibiotic treatment
• Patients with a history of severe neurological or psychiatric disorders that impair trialparticipation, including dementia, epilepsy, severe depression, and mania;8. Drug abuse, or medical, psychological, or social conditions that may interfere with studyparticipation or result evaluation
• Women with a positive serum pregnancy test or who are breastfeeding
• Clinically significant heart disease, including unstable angina, acute myocardial infarction within6 months prior to randomization, congestive heart failure with New York Heart Association(NYHA) functional class IIl or IV, or left ventricular ejection fraction <50%
• Patients with lymphoma involving the central nervous system (CNS)
• Patients with grade >2 neuropathy
• Patients deemed ineligible by the investigator